Company intelligence / Profile preview

Pebble Accelerator

Hong Kong, Hong Kong SAR

Ownership: Private
Development stage: Other

Overview

Pebble Accelerator is a boutique accelerator centered on supporting early-stage, biomedical innovation companies. Its notable collaboration is a joint antibody-based weight loss therapeutic in preclinical development with Great Bay Bio and Uni-Bio Science, aiming to reduce common side effects found in existing weight loss drugs.

Therapeutic areas: Endocrinology
Modalities: AntibodyBiologic
Industry: Investors

Partnerships

Great Bay BioUni-Bio Science GroupTigermed

Beyond the preview

Go deeper on Pebble Accelerator.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pebble Accelerator.

Explore the full profile